Supernus to Present at Jefferies Healthcare Conference in June
May 21 2014 - 4:08PM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company, today announced that the Company's
management will provide a business update and will be hosting
investor meetings during the Jefferies Healthcare Conference.
Date: Wednesday, June 4
Presentation Time: 11:00 am ET Place: Grand Hyatt
Hotel, NYC
Investors interested in arranging a meeting during this
conference should contact via email Isabel Zakoscielny at
izakoscielny@jefferies.com.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR™ (extended-release
topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in
ADHD, including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD
and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591
or
Investor Contact:
Cockrell Group
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2024 to May 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From May 2023 to May 2024